Trial · NCT00452530
Results by group92
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 92
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period | Apixaban, 2.5 mg BID + Placebo | 1.09 | 95% Confidence Interval 0.62 to 1.88 | Percentage of events/patients evaluated | |
| Rate of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During the Intended Treatment Period | Enoxaparin, 40 mg QD + Placebo | 2.17 | 95% Confidence Interval 1.47 to 3.18 | Percentage of events/patients evaluated | |
| Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM | Apixaban, 2.5 mg BID + Placebo | Major bleeding (n=9, 14) | 0.60 | 95% Confidence Interval 0.30 to 1.16 | Percentage of events/patients evaluated |
| Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM | Enoxaparin, 40 mg QD + Placebo | Major bleeding (n=9, 14) | 0.93 | 95% Confidence Interval 0.54 to 1.57 | Percentage of events/patients evaluated |
| Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM | Apixaban, 2.5 mg BID + Placebo | CRNM (n=44, 58) | 2.93 | 95% Confidence Interval 2.19 to 3.93 | Percentage of events/patients evaluated |
| Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM | Enoxaparin, 40 mg QD + Placebo | CRNM (n=44, 58) | 3.85 | 95% Confidence Interval 2.98 to 4.95 | Percentage of events/patients evaluated |
| Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM | Apixaban, 2.5 mg BID + Placebo | Major bleeding or CRNM (n=53, 72) | 3.53 | 95% Confidence Interval 2.71 to 4.60 | Percentage of events/patients evaluated |
| Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM | Enoxaparin, 40 mg QD + Placebo | Major bleeding or CRNM (n=53, 72) | 4.77 | 95% Confidence Interval 3.81 to 5.98 | Percentage of events/patients evaluated |
| Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM | Apixaban, 2.5 mg BID + Placebo | Any bleeding | 6.93 | 95% Confidence Interval 5.75 to 8.34 | Percentage of events/patients evaluated |
| Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), and Major Bleeding or CRNM | Enoxaparin, 40 mg QD + Placebo | Any bleeding | 8.36 | 95% Confidence Interval 7.06 to 9.87 | Percentage of events/patients evaluated |
| Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period | Apixaban, 2.5 mg BID | 15.06 | 95% Confidence Interval 12.95 to 17.46 | Percentage of events/patients evaluated | |
| Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period | Enoxaparin, 40 mg QD | 24.37 | 95% Confidence Interval 21.81 to 27.14 | Percentage of events/patients evaluated | |
| Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome | Apixaban, 2.5 mg BID + Placebo | SAE | 72 | Participants | |
| Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome | Enoxaparin, 40 mg QD + Placebo | SAE | 88 | Participants | |
| Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome | Apixaban, 2.5 mg BID + Placebo | Bleeding AE | 90 | Participants | |
| Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome | Enoxaparin, 40 mg QD + Placebo | Bleeding AE | 112 | Participants | |
| Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome | Apixaban, 2.5 mg BID + Placebo | Discontinuations due to AEs | 40 | Participants | |
| Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome | Enoxaparin, 40 mg QD + Placebo | Discontinuations due to AEs | 44 | Participants | |
| Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome | Apixaban, 2.5 mg BID + Placebo | Deaths | 2 | Participants | |
| Number of Participants With Serious Adverse Events (SAE), Bleeding Adverse Events (AEs), Discontinuations Due to AEs, and Death as Outcome | Enoxaparin, 40 mg QD + Placebo | Deaths | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00452530/results